Biogen bets $1.5B on Sage's once-failed depression drug

Biogen is paying $1.5 billion upfront for a stake in Sage Therapeutics’ once-failed depression therapy zuranolone and an earlier-phase asset. The agreement gives Biogen rights to a drug that is closing in on data from three late-phase trials that will shape its future.